Showing 2221-2230 of 2494 results for "".
- Alcon to Acquire Eysuvis and Inveltys from Kala Pharmaceuticalshttps://modernod.com/news/kala-pharmaceuticals-to-sell-eysuvis-and-inveltys-to-alcon/2480878/Alcon will significantly bolster its pharmaceutical offerings after reaching an agreement to acquire Kala Pharmaceuticals' commercial portfolio, which includes dry eye drug Eysuvis (loteprednol etabonate suspension 0.25%), and Inveltys (loteprednol etabonate
- Bausch + Lomb Announces Launch of IPOhttps://modernod.com/news/bausch-lomb-announces-launch-of-ipo/2480816/Bausch + Lomb announced the launch of its initial public offering (IPO) and the commencement of the roadshow for the IPO. Bausch + Lomb, which is being spun out of Bausch Health, plan to sell 35 million common shares for $21 to $24 per share, for a valuation of as much $8.4 billion
- Ziemer Receives FDA Clearance for the FEMTO Z8 NEOhttps://modernod.com/news/ziemer-receives-fda-clearance-for-the-femto-z8-neo/2480792/Ziemer Ophthalmic Systems has received FDA clearance for its latest femtosecond laser, the FEMTO Z8 NEO—the successor of Femtosecond Laser LDV Z8. The FEMTO Z8 NEO provides advanced hardware, as well as new and improved software applications. The newly designed platform offer
- Luneau Technology Launches as 'Visionix' to Manufacture and Sell Optovue, Visionix, Briot and Weco Brandshttps://modernod.com/news/luneau-technology-launches-as-visionix-to-manufacture-and-sell-optovue-visionix-briot-and-weco-brands/2480736/Luneau Technology Group recently announced that it will take on 'Visionix' as its official global name beginning March 31, 2022, unveiling a combined booth at Vision Expo East. As mentioned in the recent global announcement, 'Optovue' will transition to a product brand f
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- Lighthouse Guild Opens Technology Center for People Who are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/Lighthouse Guild Technology Center, which offers people who are blind or visually impaired access to the latest assistive devices and state-of-the-art technology, celebrated its official opening. The Center occupies 11,000 square feet at Lighthouse Guild’s New York City headquarters and is
- 1-800 Contacts Announces New Company Focused on B2B Vision Technologies and Serviceshttps://modernod.com/news/1-800-contacts-announces-new-company-focused-on-b2b-vision-technologies-and-services/2480662/1-800 Contacts recently announced the formation of a standalone business, Luna Solutions, focused on providing technology and services to third parties in the vision space. The company offers 20 integrated technologies and services–ranging from telehealth platforms for n
- TearSolutions Meets with FDA and Announces Next Steps in the Development of Lacripephttps://modernod.com/news/tearsolutions-meets-with-fda-and-announces-next-steps-in-the-development-of-lacripep/2480661/TearSolutions, the developer of a replacement therapy for the treatment of dry eye disease (DED) called Lacripep, announced that in late 2021 it received official minutes from a Type C meeting with the FDA regarding the development of Lacripep for the treatment of DED and is planni
- Nicox Granted New Patent for NCX 4251 in Japanhttps://modernod.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/Nicox SA announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the company’s product candidate NCX 4251. Patent JP.7021301 covers ophthalmic suspensions comprising a specific form of fluticasone p
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses-1/2480648/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s MyReaderNumber app is available for download for a one-time fee of $2.99 on the App Store (iOS only; available for iPhone X and newer) and c